Cara Community

Community Discussion

In our community we students of the market openly discuss our various market insights and thoughtful opinions in support of a wider understanding of price behavior. Join us and share your thoughts!

9048
Leave a Reply

Please Login to comment
9048 Comment threads
0 Thread replies
12 Followers
 
Most reacted comment
Hottest comment thread
88 Comment authors
baz22skylerBill CarakaimuJimG Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  Subscribe  
newest oldest
Notify of
baz22
Member
baz22

My Sage hedge is Axsome … pulled back some on Blueprint today.. negative action.. will watch trades close tomorrow.

baz22
Member
baz22

Did add more Edit today. As Crsp is doing fantastic clinicals with Sickle Cell and TDT using ‘ ex-vivo ‘ Crispr cell treatment [cells taken outside the body, re-engineered, and then infused back in the body ] …. Editas is doing Crispr therapy with LCA 10 blindness using ‘ in-vivo ‘ editing [ inside the body ]. The LCA 10 trial is the first ever in-vivo crispr therapy in the US. If successful, the implications for this type of gene editing would be a quicker and more convenient procedure for the patient. Only time will tell, and Crispr Therapeutics will… Read more »

baz22
Member
baz22

Maybe $ 90 – $ 110 , after looking at CMO & CEO options taken in September, 2019

baz22
Member
baz22

Started Sage (after hours) … reminded that Prozac needed repeated attempts to get it right. Need to realize Sage’s first FDA approved ( in March ) ‘ Zulresso,’ although infusion, is still the gold standard and is light years faster in effectiveness than any other post-partum depression therapy available. Speed of efficacy is tremendously important in severe depression scenarios. Sage 217 will undergo new trials after discussions with FDA…If there was ever a positive buyout after bad news, Sage is it… As just a guess, I think $ 120.00…..

skyler
Member
skyler

suncoke $5.45 up 6% today following b. riley upgrade. off its highs though.
https://finviz.com/quote.ashx?t=SXC&ty=c&ta=1&p=d

earning one month ago. “. . earnings of $0.13 per share on revenue of $404.3 million. The consensus earnings estimate was $0.09 per share on revenue of $359.1 million. Revenue grew 10.9% on a year-over-year basis.”
https://www.earningswhispers.com/epsdetails/sxc
https://finviz.com/quote.ashx?t=SXC&ty=c&ta=1&p=d

re buybacks: well put Bill

skyler
Member
skyler

eia natural gas: -19Bcf 591 Bcf higher than last year at this time and 9 Bcf below the five-year average.
http://ir.eia.gov/ngs/ngs.html

skyler
Member
skyler

gm. dupont $61.93 at 52 week lows, post earnings oct. 31st it traded up to ~$72
https://www.earningswhispers.com/epsdetails/dd
https://finviz.com/quote.ashx?t=dd&ty=c&ta=1&p=d

the index has been down since early november: https://stockcharts.com/h-sc/ui?s=$DJUSCH

baz22
Member
baz22

You’re welcome, skyler. Scatter is good…. you will be processing a wealth of information from many, many locations… just remember to take notes…… and where you put them !! …. ** also, congratulations to Canada’s ‘ AUPH ‘ tonight… up 119 % after market.

baz22
Member
baz22

* damn touchscreen…. ” if so, it really bodes well for their work together on Hepatitis B virus. “. A cure, not just remission or suppression…. if Institutional, probably won’t show up at SEC filings till next quarter updates ( sometime in January, 2020 ).

baz22
Member
baz22

Wow …. after market… Dicerna ( DRNA ) had a 1,500,000 share block buy at $ 24.73, and a 500,000 share block buy at $ 24.75. These were the last two trades of the day at 5:58 PM and 5:59 pm….. No other trades afterward… appx. 67,000 shares had traded up to that point, at an average price of $ 26.90…. got to be institutional…. perhaps Roche bought another chunk of the company… if so., really bodies well ffg or th err or work on Hepatitis B th together,…

skyler
Member
skyler

great baz22 was hoping you’d respond. btw your knowledge on these biotechs really requires alot
of study and reading. i’ve been trying recently it’s alot of work, though i have an advantage of being
scatter-brained ;D. anyways thankyou for keeping us apprized.

baz22
Member
baz22

Good, full read on Ionis at Seeking Alpha tonight, before it’s relocated to ‘ subscription only ‘ ..